FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| 4DX | $5.27 |
|
$7.55 | $0.23 |
$3.75 |
|
|
| AT1 | $0.03 | 0.00% | $0.05 | $0.01 |
|
||
| BB1 | $0.68 |
|
$1.11 | $0.31 |
|
||
| BRN | $0.16 | 0.00% | $0.29 | $0.13 |
|
||
| CAT | $3.23 |
|
$7.72 | $2.90 |
$5.356 |
|
|
| CBL | $0.06 | 0.00% | $0.09 | $0.03 |
|
||
| CGS | $2.42 |
|
$2.97 | $1.21 | 26.0 |
$3.20 |
|
| CMP | $0.30 |
|
$0.45 | $0.24 |
|
||
| COH | $95.00 |
|
$319.56 | $91.33 | 23.3 |
$116.528 |
|
| CSX | $0.45 | 0.00% | $0.88 | $0.37 |
|
||
| CTE | $1.05 |
|
$1.30 | $0.66 |
|
||
| CU6 | $2.96 |
|
$5.87 | $1.84 |
$6.50 |
|
|
| CVB | $0.06 | 0.00% | $0.18 | $0.05 |
|
||
| EBR | $0.60 |
|
$1.48 | $0.57 |
$2.235 |
|
|
| EMV | $1.82 |
|
$2.43 | $1.48 |
$3.15 |
|
|
| EYE | $0.14 | 0.00% | $0.21 | $0.10 |
|
||
| FPH | $29.94 |
|
$35.31 | $29.58 | 43.5 |
|
|
| IME | $0.39 | 0.00% | $0.47 | $0.22 | 18.6 |
$0.50 |
|
| IMR | $2.05 |
|
$2.25 | $1.15 |
$2.71 |
|
|
| IPD | $0.02 | 0.00% | $0.06 | $0.01 |
$0.043 |
|
|
| LDX | $0.17 | 0.00% | $0.33 | $0.02 |
|
||
| MX1 | $0.06 | 0.00% | $0.12 | $0.04 |
$0.16 |
|
|
| NAN | $3.60 |
|
$5.08 | $3.21 | 63.2 |
$3.80 |
|
| ONE | $0.18 |
|
$0.41 | $0.17 |
$0.45 |
|
|
| PCK | $0.15 | 0.00% | $0.35 | $0.03 |
|
||
| PEB | $0.15 | 0.00% | $0.22 | $0.07 |
|
||
| PGC | $0.16 | 0.00% | $0.45 | $0.16 | 10.7 |
$0.315 |
|
| PME | $141.63 |
|
$336.00 | $107.75 | 77.5 |
$224.167 |
|
| RAP | $0.05 | 0.00% | $0.07 | $0.03 |
|
||
| RMD | $30.96 |
|
$45.25 | $30.66 | 18.5 |
$46.658 |
|
| SHG | $0.22 | 0.00% | $0.42 | $0.19 |
|
||
| SOM | $0.57 |
|
$0.95 | $0.40 | 35.6 |
$0.99 |
|
| TRJ | $0.42 | 0.00% | $0.97 | $0.37 | 16.8 |
$1.025 |
|
2.93% 
-28.8% Previous Stories
ResMed: The Recovery Has Begun
Jan 23 2024
Michael Gable of Fairmont Equities observes market dynamics for ResMed have changed for the better with price action suggesting higher prices are on the cards
Dr Boreham’s Crucible: Pro Medicus
Oct 23 2023
Tim Boreham highlights the significance of a new contract win for Pro Medicus and the company’s AI capacity
Dr Boreham’s Crucible: Cyclopharm
Oct 09 2023
FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports
Dr Boreham’s Crucible: Painchek
Sep 11 2023
Tim Boreham highlights a device used to detect pain in non-verbal patients, such as those suffering dementia and infants
Margins Signal Integral Diagnostics Recovery
Sep 07 2023
Analysts identify a second half FY23 inflection point for Integral Diagnostics
ResMed: Finding A Base?
Aug 15 2023
After a sharp pullback for ResMed, Michael Gable of Fairmont Equities suggests a base may soon be formed, providing a buying opportunity
August Turns ResMed Into Nigel NoMates
Aug 09 2023
A miss on the Q4 gross margin and Eli Lilly targeting the CPAP market have kept ResMed shares under selling pressure since Friday last week
Dr Boreham’s Crucible: Lumos Diagnostics
Jun 19 2023
Tim Boreham takes a look at Lumos Diagnostics, which specialises in rapid point-of-care tests to help healthcare professionals diagnose and manage medical conditions more accurately
Fisher & Paykel Healthcare: Lower Margin, Higher Spending
May 30 2023
Following FY23 results for Fisher & Paykel, brokers lowered earnings forecasts on a delayed margin recovery and future spending plans
Dr Boreham’s Crucible: Impedimed
May 08 2023
Tim Boreham reports a change in CEO has given cancer monitoring biotech Impedimed a new lease of life
Latest News
| 1 |
ASX Winners And Losers Of Today – 23-04-26Apr 23 2026 - Daily Market Reports |
| 2 |
Rudi’s View: Best Buys & Conviction CallsApr 23 2026 - Rudi's View |
| 3 |
Cochlear’s Shock Downgrade Raises ConcernsApr 23 2026 - Australia |
| 4 |
George Noble Interview: Investing For The FutureApr 23 2026 - International |
| 5 |
The Short Report – 23 Apr 2026Apr 23 2026 - Weekly Reports |